Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Chubb
Citi
US Department of Justice
McKesson
Moodys

Generated: May 25, 2018

DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for osimertinib mesylate and what is the scope of osimertinib mesylate freedom to operate?

Osimertinib mesylate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has eighty-one patent family members in thirty-eight countries.

There is one drug master file entry for osimertinib mesylate. One supplier is listed for this compound.
Summary for osimertinib mesylate
International Patents:81
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Suppliers / Packagers: 1
Bulk Api Vendors: 25
Clinical Trials: 542
Patent Applications: 3
DailyMed Link:osimertinib mesylate at DailyMed
Synonyms for osimertinib mesylate
1421373-66-1
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1)
AK198680
AKOS026673944
AZD 9291 mesylate
AZD-9291 (Mesylate)
AZD-9291 mesylate
AZD-9291 mesylate pound Osimertinib Mereletinib)
AZD9291 mesylate
AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt
BC600811
CHEBI:90948
CHEMBL3545063
D10766
EX-A1577
FT-0699962
HY-15772A
KS-00000SU8
Mereletinib mesylate
MFCD28137994
MolPort-044-560-736
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate
Osimertinib mesilate (JAN)
Osimertinib mesylate (USAN)
Osimertinib mesylate [USAN]
osimertinib methanesulfonate
osimertinib monomesylate
RDL94R2A16
SCHEMBL14661152
Tagrisso (TN)
UNII-RDL94R2A16

US Patents and Regulatory Information for osimertinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Julphar
Queensland Health
Accenture
Moodys
Daiichi Sankyo
Cantor Fitzgerald
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.